> San Francisco-based Five Prime and Boehringer Ingelheim have agreed to collaborate on new drug therapies in a deal worth up to $75 million. The two companies will work on rheumatoid arthritis and other diseases. Report
> The FDA has extended its review of Cephalon's experimental ADHD drug by three months. Report
> Protez Pharmaceuticals of Malvern, PA has added $6 million to its second round of venture capital. Release
> France's Transgene released positive Phase II data for its experimental vaccine TG4001 and announced that it could partner with either Merck or GlaxoSmithKline. Report
> Teva got final approval from the FDA for a generic version of Pravachol following a court ruling to lift an injunction blocking a copycat version of Bristol-Myers Squibb's blockbuster cholesterol-lowering drug. Bristol-Myers Squibb's patent on Pravachol ended April 20. Last year, the drug had $1.3 billion in sales. Report
> Rexahn of Rockville, MD has agreed to sell regional sales rights to three of its experimental drugs to Korea's Future Systems for $35.8 million while agreeing to buy $35 million in the Korean company's stock. Release
> Alcon and Amgen have agreed to collaborate on new therapies for eye diseases. Release
> Astex Therapeutics announced that the FDA has approved its IND application for the clinical development of its proprietary Aurora Kinase inhibitor, AT9283, for cancer. Release
And Finally… A new report from PhRMA hopes to rebut critics who insist that drug makers are solely interested in blockbuster drugs. Report